

Nocarasins A–C and Brasiliquinone D, New Metabolites from the Actinomycete *Nocardia brasiliensis*

Masashi Tsuda,[†] Akira Nemoto,[‡] Hisayuki Komaki,[‡] Yasushi Tanaka,[‡] Katsukiyo Yazawa,[§] Yuzuru Mikami,[§] and Jun'ichi Kobayashi^{*†}

Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan, Research Laboratory, Higeta Shoyu Co., Ltd., Chiba 288-8680, Japan, and Research Center for Pathogenic Fungi and Microbial Toxicoses, Chiba University, Chiba 260-8673, Japan

Received June 2, 1999

Four new metabolites, nocarasins A–C (**1–3**) and brasiliquinone D (**4**), have been isolated from the actinomycete *Nocardia brasiliensis* IFM 0667, and the structures were elucidated on the basis of spectroscopic data and chemical means. Nocarasins A–C (**1–3**) and brasiliquinone D (**4**) exhibited cytotoxicity and antibacterial activity.

During our search for bioactive substances from pathogenic actinomycetes of the genus *Nocardia*, we previously isolated a cytotoxic anthracycline,¹ a 32-membered macrolide possessing immunosuppressive and antifungal activity,² three benz[*a*]anthraquinones with cytotoxic and antibacterial activity,³ a cytotoxic indole alkaloid,⁴ and a tricyclic terpenoid with immunosuppressive and cytotoxic activity.⁵ Recently, an investigation of extracts of *Nocardia brasiliensis* IFM 0667 resulted in the isolation of four new metabolites, nocarasins A–C (**1–3**) and brasiliquinone D (**4**). Here we describe the isolation and structure elucidation of **1–4**.

Results and Discussion

The mycelia of *N. brasiliensis* IFM 0667 were extracted with MeOH, and the Et₂O-soluble materials of the extract were subjected to Si gel column chromatography (hexane–EtOAc and then EtOAc–MeOH), followed by C₁₈ HPLC (CH₃CN–H₂O) to yield nocarasins A (**1**, 13 mg), B (**2**, 3 mg), and C (**3**, 5 mg) and brasiliquinone D (**4**, 1 mg), together with known compounds, brasiliquinones A (**6**) and C.³

The molecular formula of nocarasin A (**1**), a colorless oil, was revealed to be C₁₇H₂₄O₂ by HREIMS [*m/z* 260.1787 (M⁺), Δ +1.0 mmu]. An IR band at 3370 cm⁻¹ was attributed to hydroxyl group(s). UV absorptions [λ_{max} (MeOH) 279 (ε 2500) and 226 nm (6000)] and the three aromatic proton signals [H-2, δ_H 6.83 (d, *J* = 1.5 Hz); H-4, δ_H 6.84 (dd, *J* = 1.5, 8.0 Hz); H-5, δ_H 7.09 (d, *J* = 8.0 Hz)] in the ¹H NMR spectrum were characteristic of a 1,2,4-trisubstituted benzene ring. The ¹³C NMR (Table 1) spectrum, including DEPT experiments, disclosed five sp² quaternary carbons, five sp² methines, four sp³ methylenes (one oxygenated), and three methyl signals. The relatively lower-field sp² carbon signal at δ_C 154.6 (C-1) and a deuterium-exchangeable proton at δ_H 5.05 (OH-1) were suggestive of the presence of a phenolic hydroxyl group. The chemical shifts of three singlet methyl signals (H₃-14, δ_H 1.63; H₃-15, 1.60; H₃-16, 1.76) indicated that these were vinyl methyl groups. The ¹H–¹H COSY spectrum of **1** implied the connectivities of C-2–C-5, C-7–C-8, and C-10–C-12. HMBC correlations from H₃-16 to C-8, C-9, and C-10 revealed connections among C-8, C-10, and C-16 through

an sp² quaternary carbon of C-9. Two vinyl methyl proton signals (H₃-14 and H₃-15) showed long-range correlations for C-12 and C-13, suggesting that both methyl groups were attached to C-13. The trisubstituted benzene ring was attached to the methylene carbon at C-7 from HMBC correlations from H₂-7 to C-1, C-5, and C-6. The oxymethylene carbon (C-17) and a phenolic hydroxyl group were connected at C-3 and C-1, respectively, judging from HMBC correlations from H₂-17 to C-2, C-3, and C-4, and from H-5 to C-1. The presence of two hydroxyl groups at C-1 and C-17 was established by acetylation of **1**. In the ¹H NMR spectrum of the diacetate (**5**), two methyl signals (δ_H 2.08 and 2.31) of acetyl groups were observed, and the oxymethylene proton signal at C-17 was shifted to the lower field (δ_H 5.22). Thus, the structure of nocarasin A was concluded to be **1**.

Nocarasin B (**2**), a colorless oil, was revealed to possess the molecular formula, C₁₈H₂₄O₃, by HREIMS [*m/z* 288.1722 (M⁺), Δ -0.3 mmu]. The IR spectrum indicated the presence of hydroxyl (3325 cm⁻¹) and ester carbonyl (1725 cm⁻¹) groups. ¹H and ¹³C NMR data (Table 1) revealed that **2** possessed an ester carbonyl, five sp² quaternary carbons, five sp² methines, three sp³ methylenes, one methoxy, and three vinyl methyl groups. Extensive analyses of 2D NMR data implied that the structure of **2** was the same as that of **1** except for the substituent at C-3. The existence of the methoxycarbonyl group at C-3 was deduced from HMBC correlations from H-2, H-4, and 17-OCH₃ to C-17. Thus, the structure of nocarasin B was assigned as **2**. This was supported by conversion of **2** into **1** by LiAlH₄ reduction.

HREIMS [*m/z* 302.1891 (M⁺), Δ +0.9 mmu] of nocarasin C (**3**) established the molecular formula as C₁₉H₂₆O₃, corresponding to the methyl ether of nocarasin B (**2**). The ¹H and ¹³C NMR data (Table 1) were analogous to those of **2**. The ¹³C NMR spectrum contained two methoxy signals [δ_C 55.6 (1-OCH₃) and 52.0 (17-OCH₃)], one of which was not observed for **2**. The HMBC spectrum revealed the H–C long-range correlation from 1-OCH₃ to C-1. Thus, nocarasin C (**3**) was concluded to be 1-*O*-methyl form of nocarasin B (**2**).

Brasiliquinone D (**4**, [α]_D²³ +87° (c 0.40, CHCl₃)) was a red amorphous solid, and the molecular formula was elucidated as C₂₈H₂₉NO₈ by HRFABMS [*m/z* 507.1872 (M⁻), Δ -2.1 mmu], corresponding to the monoacetate of brasiliquinone A³ (**6**). The ¹H and ¹³C NMR data of **4** were similar to those of **6**. The ¹H NMR spectrum showed an amide (δ_H 8.52) and an acetyl methyl proton signal (δ_H 2.28), sug-

* To whom correspondence should be addressed. Tel.: (011) 706-4985. Fax: (011) 706-4989. E-mail: jkobay@pharm.hokudai.ac.jp.

[†] Hokkaido University.

[‡] Higeta Shoyu Co., Ltd.

[§] Chiba University.

Table 1. ^1H and ^{13}C NMR Data of Nocarasin A (**1**), B (**2**), and C (**3**) in CDCl_3


position	1			2		3	
	δ_{C}	δ_{H} (m, Hz)	HMBC (H)	δ_{C}	δ_{H} (m, Hz)	δ_{C}	δ_{H} (m, Hz)
1	154.6 s		5, 7	154.3 s		157.3 s	
2	114.5 d	6.83 (d, 1.5)	4, 17	122.1 d	7.51 (d, 1.3)	110.9 d	7.49 (d, 1.2)
3	140.5 s		5, 17	132.9 s		135.9 s	
4	119.2 d	6.84 (dd, 1.5, 8.0)	2, 17	116.6 d	7.54 (dd, 1.3, 7.7)	122.1 d	7.58 (dd, 1.2, 7.8)
5	130.1 d	7.09 (d, 8.0)	7	129.8 d	7.17 (d, 7.7)	129.0 d	7.19 (d, 7.8)
6	126.5 s		4, 7	129.4 s		126.8 s	
7	29.4 t	3.36 ^a (d, 7.1)	5	29.5 t	3.41 ^a (m)	28.4 t	3.36 ^a (m)
8	121.7 d	5.32 (t, 7.1)	7, 16	120.8 d	5.31 (br t, 7.0)	121.5 d	5.30 (br t, 7.7)
9	138.4 s		7, 16	139.0 s		137.0 s	
10	39.7 t	2.09 ^a (m)	8, 11, 16	39.7 t	2.09 ^a (m)	39.8 t	2.06 ^a (m)
11	26.5 t	2.12 ^a (m)	10	26.5 t	2.12 ^a (m)	26.7 t	2.10 ^a (m)
12	124.0 d	5.08 (br t, 5.9)	14, 15	123.9 d	5.07 (br t, 5.4)	124.3 d	5.10 (br t, 5.1)
13	131.9 s		14, 15	132.0 s		131.5 s	
14	25.7 q	1.63 ^b (s)	15	25.7 q	1.69 ^b (s)	25.7 q	1.68 ^b (s)
15	17.7 q	1.60 ^b (s)	14	17.7 q	1.60 ^b (s)	17.7 q	1.60 ^b (s)
16	16.2 q	1.76 ^b (s)	8	16.2 q	1.75 ^b (s)	16.0 q	1.69 ^b (s)
17	65.1 t	4.61 ^a (s)	2, 4	167.1 s		167.3 s	
1-OH		5.05 (br)			5.59 (br s)		
1-OCH ₃				55.6 q	3.89 ^b (s)		
17-OCH ₃				52.1 q	3.89 ^b (s)	52.0 q	3.90 ^b (s)

^a 2H. ^b 3H.**Table 2.** Antimicrobial Activity of Nocarasin A–C (**1–3**) and Brasiliquinone D (**4**)^a

test organisms	MIC ($\mu\text{g/mL}$)				
	1	2	3	4	rifampicin
<i>Nocardia asteroides</i>	3.13	1.56	>25	1.56	50
<i>Gordonia bronchialis</i>	0.39	0.78	25	0.78	0.39
<i>Mycobacterium smegmatis</i>	6.25	6.25	>25	12.5	12.5
<i>Bacillus subtilis</i> PCI189	6.25	1.56	>25	6.25	<0.02
<i>Micrococcus luteus</i>	>25	>25	>25	25	<0.02
<i>Escherichia coli</i> NIHJC2	>25	>25	>25	>25	3.13
<i>Aspergillus niger</i>	25	>25	>25	>25	>100
<i>Candida albicans</i>	>25	>25	>25	>25	>100
<i>Cryptococcus neoformans</i>	>25	>25	>25	>25	>100

^a Mueller–Hinton broth and Sabouraud dextrose broth were used for bacteria and fungi, respectively.

gesting that **4** was the 3'-*N*-acetyl form of brasiliquinone A (**6**). The absolute stereochemistry of **4** was established



to be the same as that of **6**, because all spectral data of the diacetate³ (**7**) of **4** were identical with those of the triacetate of **6**.

Nocarasin A–C (**1–3**) are new benzenoid metabolites with a geranyl side chain, while brasiliquinone D (**4**) is a new benz[*a*]anthraquinone with an ethyl group at C-3. Compounds **1**, **2**, and **4** showed inhibitory activity against some Gram-positive bacteria, especially against acid-fast bacteria such as *Nocardia asteroides* (MIC 3.13, 1.56, and 1.56, $\mu\text{g/mL}$, respectively), *Gordonia bronchialis* (MIC 0.39, 0.78, and 0.78, $\mu\text{g/mL}$, respectively), and *Mycobacterium smegmatis* (MIC 6.25, 6.25, and 12.5, $\mu\text{g/mL}$, respectively) (Table 2). On the other hand, there was almost no activity in compound **3**, indicating that the phenolic hydroxyl group at C-1 was important for the activity. Nocarasin A–C (**1–3**) exhibited cytotoxicity against HL-60 human promyelocytic leukemia cells in vitro, with IC₅₀ values of 0.91, 0.51, and 0.60 $\mu\text{g/mL}$, respectively, while brasiliquinone D (**4**) showed weak cytotoxicity against murine leukemia L1210 (IC₅₀, 11 $\mu\text{g/mL}$) and KB human epidermoid carcinoma cells (IC₅₀, 20 $\mu\text{g/mL}$) in vitro.

Experimental Section

General Methods. The IR and UV spectra were recorded on a JASCO FT/IR-5300 and JASCO Ubest-35 spectrophotometer, respectively. ^1H and ^{13}C NMR spectra were recorded on a Bruker ARX-500 and JEOL EX-400 spectrometer, respectively. EIMS were recorded on a JEOL DX-303 spectrometer. FABMS were obtained on a JEOL HX-110 spectrometer using nitrobenzyl alcohol as a matrix. Antimicrobial activities were determined by the microbroth dilution method using

brain heart infusion (BHI) medium. Cytotoxic activities were determined by the method described.⁶ Adriamycin was included as a positive drug control: IC₅₀ 0.01 (HL-60), 0.09 (L1210), and 0.97 μg/mL (KB).

Cultivation, Extraction, and Isolation. The voucher specimen (*Nocardia brasiliensis* IFM 0667) was deposited at the Center for Pathogenic Fungi and Microbial Toxicoses, Chiba University. *N. brasiliensis* IFM 0667 strain was cultivated at 32 °C for 4 days in a 15-L jar-fermenter containing nutrient broth medium [glucose (2.0%), glycerol (2.0%), polypeptone (1.0%), and meat extract (0.5%) in H₂O at pH 7.0]. The cultured broth (15 L) was filtered, and the mycelial cake was extracted with MeOH (3 L). The Et₂O-soluble materials of the extract were subjected to Si gel column chromatography (hexane–EtOAc, 40:1, 20:1, and 5:1 and then EtOAc–MeOH, 1:1) and C₁₈ HPLC (Soken Pak ODS-W S-15/30, Soken Chemical & Engineering Co., Ltd., 25 × 250 mm; CH₃CN–H₂O, 10:90 to 90:10, 90 min; flow rate 30 mL/min; UV detection at 230 nm) to afford nocarasin A (**1**, 13 mg, *t*_R 33.5 min, from fraction eluting with hexane–EtOAc, 40:1), B (**2**, 3 mg, *t*_R 41.4 min, from fraction eluting with hexane–EtOAc, 20:1), and C (**3**, 5 mg, *t*_R 49.6 min, from fraction eluting with hexane–EtOAc, 5:1) and brasiliquinone D (**4**, 1 mg, *t*_R 29.5 min, from fraction eluting with EtOAc–MeOH, 1:1).

Nocarasin A (1): a colorless oil; IR (neat) ν_{\max} 3370 (br), 2920, and 1620 cm⁻¹; UV (EtOH) λ_{\max} 279 (ε 2500) and 226 nm (6000); ¹H and ¹³C NMR, see Table 1; EIMS *m/z* 260 (M⁺); HREIMS *m/z* 260.1787 (M⁺), calcd for C₁₇H₂₄O₂, 260.1777.

Nocarasin B (2): a colorless oil; IR (neat) ν_{\max} 3325 (br), 2925, and 1725 cm⁻¹, UV (EtOH) λ_{\max} 280 (ε 3500) and 245 nm (8000); ¹H and ¹³C NMR, see Table 1; EIMS *m/z* 288 (M⁺); HREIMS *m/z* 288.1722 (M⁺), calcd for C₁₈H₂₄O₃, 288.1725.

Nocarasin C (3): a colorless oil; IR (neat) ν_{\max} 2930 and 1720 cm⁻¹, UV (EtOH) λ_{\max} 279 (ε 4000) and 250 nm (10 000); ¹H and ¹³C NMR, see Table 1; EIMS *m/z* 302 (M⁺); HREIMS *m/z* 302.1891 (M⁺), calcd for C₁₉H₂₆O₃, 302.1882.

Brasiliquinone D (4): a red amorphous solid; [α]_D²³ +87° (c 0.40, CHCl₃); IR (neat) ν_{\max} 3360, 2925, 1680, and 1630 cm⁻¹; UV (EtOH) λ_{\max} 413 (ε 8300), 268 (34 000), and 215 nm (39 000); ¹H NMR (CDCl₃) δ 1.01 (3H, t, *J* = 7.4 Hz, H₃-14), 1.26 (3H, d, *J* = 6.1 Hz, H₃-6'), 1.53 (2H, m, H₂-13), 2.18 (1H, m, H-2), 2.24 (1H, br d, *J* = 15.0 Hz), 2.28 (3H, s, 3'-NAC), 2.34 (1H, dt, *J* = 15.0, 3.9 Hz, H-2'), 2.55 (1H, dd, *J* = 11.2, 15.9 Hz), 2.66 (1H, br dd, *J* = 10.9, 16.6 Hz, H-4), 2.93 (1H, dd, *J* = 4.7, 15.9 Hz, H-2), 2.97 (1H, br dd, *J* = 3.6, 16.6 Hz, H-4), 3.60 (1H, dd, *J* = 3.6, 9.7 Hz, H-4'), 3.86 (1H, dq, *J* = 9.7, 6.1 Hz, H-5'), 4.68 (1H, m, H-3'), 5.76 (1H, br d, *J* = 3.0 Hz, H-1'), 7.01 (1H, s, H-5), 7.66 (1H, d, *J* = 8.3 Hz, H-9), 7.76 (1H, dd, *J* = 7.5, 8.3 Hz, H-10), 7.84 (1H, d, *J* = 7.5 Hz, H-11), 8.52 (1H, br d, *J* = 6.3 Hz, NH-3'), and 12.95 (1H, s, OH-6); ¹³C NMR (CDCl₃) δ 11.1 (q, C-14), 17.4 (q, C-6'), 23.0 (q, 3'-NAC), 28.8 (t, C-13), 33.3 (t, C-2'), 36.5 (t, C-4), 37.0 (d, C-3),

45.7 (t, C-2), 47.2 (d, C-3'), 66.2 (d, C-5'), 74.5 (d, C-4'), 95.8 (d, C-1'), 117.6 (s, C-6a), 119.6 (s, C-7a), 120.3 (d, C-9), 121.2 (d, C-11), 121.4 (d, C-5), 124.2 (s, C-12b), 136.9 (d, C-10), 137.5 (s, C-12a), 137.6 (s, C-11a), 152.9 (s, C-4a), 157.2 (s, C-8), 163.6 (s, C-6), 174.3 (s, 3'-NAC), 183.9 (s, C-12), 189.4 (s, C-7), and 198.0 (s, C-1); FABMS (neg.) *m/z* 507 (M⁻); HRFABMS *m/z* 507.1872 (M⁻), calcd for C₂₈H₂₉NO₈, 507.1893.

Acetylation of Nocarasin A (1). Nocarasin A (**1**, 0.5 mg) was treated with acetic anhydride (100 μL) and pyridine (100 μL) at room temperature for 8 h. The mixture was evaporated in vacuo to afford compound **5** (0.5 mg), a colorless oil: IR (neat) ν_{\max} 1760 and 1730 cm⁻¹; UV (EtOH) λ_{\max} 280 (ε 2700) nm; ¹H NMR δ_H 1.60 (3H, s), 1.676 (3H, s), 1.683 (3H, s), 2.04 (2H, t, *J* = 7.4 Hz), 2.08 (3H, s), 2.09 (2H, m), 2.31 (3H, s), 3.23 (2H, d, *J* = 7.2 Hz), 5.06 (2H, s), 5.09 (1H, t, *J* = 6.5 Hz), 5.22 (1H, t, *J* = 7.2 Hz), 7.03 (1H, d, *J* = 1.0 Hz), 7.15 (1H, dd, 1.0, 7.8 Hz), and 7.23 (1H, d, *J* = 7.8 Hz); EIMS *m/z* 344 (M⁺); HREIMS *m/z* 344.1988 (M⁺), calcd for C₂₁H₂₈O₄, 344.1987.

Reduction of Nocarasin B (2) with LiAlH₄. To a solution of nocarasin B (**2**, 1 mg) in ether (200 μL) was added LiAlH₄ (2 mg) at 0 °C, and stirring was continued at room temperature for 1 h. After addition of H₂O, the reaction mixture was extracted with Et₂O, and the organic phase was washed with brine, and evaporated in vacuo. The residue was passed through a Sep-Pak silica cartridge (hexane–EtOAc, 2:1) to afford the reduction product of **2** (0.6 mg), of which physicochemical data were identical with those of nocarasin A (**1**).

Acetylation of Brasiliquinone D (4). Brasiliquinone D (**4**, 0.5 mg) was treated with acetic anhydride (100 μL) and pyridine (100 μL) at room temperature for 12 h. The solvent was removed by nitrogen stream to afford the diacetate (**6**) of **4** (0.2 mg), of which physicochemical data were identical with those of the triacetate of brasiliquinone A (**6**).

Acknowledgment. This work was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan.

References and Notes

- Mikami, Y.; Yazawa, K.; Ohashi, S.; Maeda, A.; Akao, M.; Ishibashi, M.; Kobayashi, J. *J. Antibiot.* **1992**, *45*, 995–997.
- Shigemori, H.; Tanaka, Y.; Yazawa, K.; Mikami, Y.; Kobayashi, J. *Tetrahedron* **1996**, *52*, 9031–9034.
- Tsuda, M.; Sato, Y.; Tanaka, Y.; Yazawa, K.; Mikami, Y.; Kobayashi, J. *J. Chem. Soc., Perkin Trans. 1* **1996**, 1773–1775.
- Kobayashi, J.; Tsuda, M.; Nemoto, A.; Tanaka, Y.; Yazawa, K.; Mikami, Y. *J. Nat. Prod.* **1997**, *60*, 719–720.
- Shigemori, H.; Komaki, H.; Yazawa, K.; Mikami, Y.; Nemoto, A.; Tanaka, Y.; Sasaki, T.; In, Y.; Ishida, T.; Kobayashi, J. *J. Org. Chem.* **1998**, *63* (3), 6900–6904.
- Kishi, K.; Yazawa, K.; Takahashi, K.; Mikami, Y.; Arai, T. *J. Antibiot.* **1984**, *37*, 874–852.

NP990265V